ALBT
Avalon GloboCare Corp.
NASDAQ · Real Estate · Real Estate - Services · US
$0.22
−4.25%Price chart
Jun 26Jul 1Jul 7Jul 10Jul 15Jul 20Jul 23Jul 28
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
Market Cap
$2.63M
MomentumView details →
1D Return
−4.25%
YTD Return
−81.80%
RSI (14)
31.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
Market Cap
$2.63M
RSI (14)
31.7
MomentumView details →
1D Return
−4.25%
YTD Return
−81.80%
SummaryUpdated Jun 1, 2026
Avalon GloboCare Corp. (NASDAQ:ALBT) is a biotechnology and real estate company founded in 2016 and publicly traded since March 2018. The company operates a dual business model, combining commercial real estate ownership and operations with biotechnology research and development focused on cell and gene therapies. Based in Freehold, New Jersey, Avalon has evolved from primarily a real estate investment company into a clinical-stage biotechnology firm developing innovative cancer treatments, particularly CAR-T cell therapies for blood cancers.
Similar companies
Latest newsMore news →
Avalon GloboCare Corp. issued a $250,000 promissory note to FirstFire, receiving $200,000 in gross proceeds after a $50,000 original issuance discount, with terms identical to the Dune Note.93d agoAvalon GloboCare Corp. issued a $250,000 promissory note to Dune Equity Holdings LLC, receiving $200,000 in gross proceeds after a $50,000 original issuance discount, with proceeds for working capital and general corporate purposes.93d ago